Action

PI3K/mTOR

Alt Name

Approval Jurisdiction

2020 FDA

Approved for clinical use

Malignant glioblastoma

Brutto

CAS

1382979-44-3

Commercial Vendor

Kazia Therapeutics

Compound Image

Paxalisib.png

Compound name

Paxalisib

InChI

InChI=1S/C18H22N8O2/c1-18(2)16-22-12-14(25-3-6-27-7-4-25)23-13(11-9-20-17(19)21-10-11)24-15(12)26(16)5-8-28-18/h9-10H,3-8H2,1-2H3,(H2,19,20,21)

InChI Key

LGWACEZVCMBSKW-UHFFFAOYSA-N

MW

382.40

PubChem CID

57384863

Reference

Reference 2

SMILES

CC1(C2=NC3=C(N2CCO1)N=C(N=C3N4CCOCC4)C5=CN=C(N=C5)N)C

Approved Drug List

1